Every material Form 8-K Celanese filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Celanese US Holdings, a wholly owned subsidiary of Celanese, completed a registered offering of $1.4 billion in senior notes due 2031 and 2034. Net proceeds, with available cash, will repay term loan borrowings and fund tender offers for about $1.2 billion of existing 2027 and 2028 notes, which reshapes the company's debt maturities.
$600 million of 7.000% senior notes due 2031 and $800 million of 7.375% senior notes due 2034 were issued on December 17, 2025
Proceeds, with available cash, will repay a five-year term loan due 2027 and fund tender offers for about $1.2 billion of 6.665% notes due 2027 and 6.850% notes due 2028
Celanese Corporation guarantees the notes on a senior unsecured basis; interest is payable semi-annually starting August 15, 2026
Celanese US Holdings LLC, a wholly owned subsidiary of Celanese Corporation, agreed on December 3, 2025 to sell $1.4 billion of senior notes through an underwriting agreement with BofA Securities, Inc. The notes add fixed-rate debt that the company must repay, and the filing does not state how the proceeds will be used.
$600 million of 7.000% Senior Notes due 2031 and $800 million of 7.375% Senior Notes due 2034
Underwriting Agreement dated December 3, 2025, with BofA Securities, Inc. as representative of the underwriters
Offering made under Form S-3 registration statement No. 333-271048, with a prospectus supplement dated December 2, 2025
Celanese reported a third-quarter U.S. GAAP diluted loss of $12.39 per share, driven by about $1.5 billion in Certain Items, mainly non-cash impairments in Engineered Materials. Adjusted EPS was $1.34, down from $2.41 a year earlier, and net sales fell to $2.4 billion. The company guided fourth-quarter adjusted EPS to $0.85 to $1.00 and agreed to sell its Micromax business for about $500 million to deleverage the balance sheet.
Q3 net sales were $2.4 billion, down 4% sequentially and from $2.6 billion a year earlier; adjusted EPS was $1.34 versus $2.41 in Q3 2024.
Certain Items totaled $1.5 billion, principally non-cash asset impairment losses in the Engineered Materials segment.
Q4 2025 adjusted EPS is expected to be $0.85 to $1.00, with volume declines expected from western hemisphere seasonality.
Micromax divestiture to Element Solutions Inc. at about $500 million is expected to close in Q1 2026; Q3 free cash flow was $375 million.
Celanese announced it intends to permanently cease manufacturing at its acetate tow facility in Lanaken, Belgium, during the second half of 2026, subject to a works council consultation. The company expects about $70 million to $90 million of charges excluding employee termination costs, which it has not yet estimated, so the total cost to shareholders is not yet known.
Intended closure of the Lanaken, Belgium acetate tow site, with cessation of all manufacturing expected in the second half of 2026
Expected charges of about $70 million to $90 million excluding termination costs, including about $55 million to $65 million of non-cash accelerated depreciation and about $15 million to $25 million of shutdown cash costs
Cash outflows expected during fiscal years 2026 through 2028; consultation with works council and union representatives to begin on or about October 31, 2025
About 160 employees in manufacturing and support functions may be affected; termination costs not yet estimated
Celanese and its subsidiary Celanese US Holdings signed a five-year, $1.75 billion unsecured revolving credit facility on August 11, 2025, replacing the company's 2022 revolving facility, which was terminated the same day. The company also amended its term loan credit agreement, adding a minimum fixed charge coverage ratio covenant and limits on dividend increases until a target leverage ratio is reached. The filing does not state any amount drawn under the new facility, so the effect on shareholders depends on future borrowing and covenant compliance.
Five-year, $1.75 billion unsecured revolving credit facility, including a $250 million letters of credit sublimit
Interest margin of 1.00% to 2.00% over benchmark rates and commitment fee of 0.09% to 0.35% on undrawn amounts, both tied to senior unsecured debt ratings
Covenants include a leverage ratio, a fixed charge coverage ratio and limits on dividend increases until a specified target ratio is met
Sixth Amendment to the Term Loan Credit Agreement, dated August 11, 2025, adds a minimum consolidated fixed charge coverage ratio covenant
Celanese reported second quarter 2025 net sales of $2.5 billion, up 6% from the first quarter but below $2.65 billion a year earlier, and adjusted earnings per share of $1.44 versus $2.38 in the second quarter of 2024. GAAP diluted EPS was $1.90, aided by a $77 million tax benefit. The company expects third quarter adjusted EPS of $1.10 to $1.40 and reaffirmed 2025 free cash flow of $700 to $800 million, citing softening demand in the second half.
Adjusted EPS was $1.44 versus $2.38 in Q2 2024; GAAP diluted EPS was $1.90, including a $77 million tax benefit
Net sales were $2,532 million versus $2,651 million in Q2 2024, and up 6% from $2,389 million in Q1 2025
Third quarter 2025 adjusted EPS is expected at $1.10 to $1.40; 2025 free cash flow target is $700 to $800 million, with Q2 free cash flow at $311 million
Celanese reported first quarter 2025 results on May 5, 2025, with net sales of $2.4 billion, down from $2.6 billion a year earlier, and a U.S. GAAP diluted loss per share of $0.15 versus earnings of $1.10 in the prior-year quarter. The company guided to second quarter adjusted EPS of $1.30 to $1.50 and expects 2025 free cash flow of $700 to $800 million, while also announcing an intention to fully divest the Micromax business.
Q1 2025 net sales $2.4 billion (versus $2.6 billion in Q1 2024); operating profit $168 million (versus $210 million); free cash flow negative $73 million
Adjusted EPS $0.57 versus $2.08 in Q1 2024; U.S. GAAP diluted loss per share $0.15 versus $1.10 earnings
Q2 2025 adjusted EPS guidance of $1.30 to $1.50; 2025 free cash flow target of $700 million to $800 million
2025 cost reduction target raised to approximately $120 million; intention to divest Micromax announced
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Celanese filing is on SEC EDGAR ↗. 8-K briefs of other companies →